Tuvusertib not checked
EMD Serono Research & Development Institute, Inc. · M1774
FollowEvery change as it happens, and a Monday email
Trials
3 active
9 in total · 8 in the EU
What this is
- How it works
- How it works isn't classified yet
- Tested for
- Advanced Solid Tumor
- Main trialPhase 1
- “The purpose of this study is to evaluate the safety, tolerability, pharmacokinetic, pharmacodynamic profile of M9466 with and without tuvusertib or an ARPi and early signs of clinical activity of M9466 with tuvusertib in participants with advanced solid tumors. Study details include: Study/Treatment Duration: Participants will be treated until disease progression, death, discontinuation, or End of Study. Visit Frequency: Every week in the first 2 cycles, followed by every 3 weeks in the subsequent cycles. An End of Treatment Visit and Safety Follow-up/Discontinuation Visit are scheduled after…”In the company’s words, NCT06421935 on ClinicalTrials.gov
- Other names
- M1774
Other drugs for Advanced Solid Tumor
- AvelumabEMD Serono Research & Development Institute, Inc. · Phase 3
- AlectinibRoche · Phase 3
- AtezolizumabRoche · Phase 3
- AU-011Aura Biosciences · Phase 3
- BevacizumabRoche · Phase 3
- CadonilimabAkeso · Phase 3
Coming up1
- 22 Feb 2027Phase 1 trial completes · ClinicalTrials.gov
Changes2
Last 90 days- 9 NovStatus changed: Active, not recruiting to Completed · ClinicalTrials.gov NCT04170153
- 9 NovCompletion date moved: 2026-11-30 to 2026-10-14 · ClinicalTrials.gov NCT04170153
Trials9
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1Active, not recruiting | 22 Feb 2027 | M9466 Alone or in Combination in Advanced Solid Tumors (DDriver 501) | |
| Phase 2Withdrawn | 12 Jan 2026 | Study of Avelumab and Tuvusertib in Participants With Advanced Urothelial Cancer That Has Progressed on Prior Anti-PD-(L)1 Therapy (JAVELIN DDRiver Bladder) | |
| Phase 2Completed | 11 Aug 2026 | Tuvusertib Combined With Niraparib or Lartesertib in Participants With Epithelial Ovarian Cancer (DDRiver EOC 302) | |
| Phase 1/2Completed | 15 Jul 2026 | Tuvusertib (M1774) in Combination With Cemiplimab in Participants With Non-Squamous NSCLC (DDRiver NSCLC 322) | |
| Phase 1Completed | 14 Apr 2026 | Tuvusertib (M1774) Human Mass Balance and Absolute Bioavailability Study (DDRIVER Solid Tumors 303) | |
| Phase 1Completed | 14 Jul 2026 | Study of Tuvusertib (M1774) in Combination With DNA Damage Response Inhibitor or Immune Checkpoint Inhibitor (DDRiver Solid Tumors 320) | |
| Phase 1Completed | 14 Oct 2026 | Tuvusertib (M1774) in Participants With Metastatic or Locally Advanced Unresectable Solid Tumors (DDRiver Solid Tumors 301) | |
| Phase 1/2Authorised | not given | MATRIX-IPC 2022-029 A phase I/II study evaluating Tuvusertib (M1774), an ATR Inhibitor, in combination with fulvestrant in hormone receptors-positive and HER2-negative, advanced breast cancers, resistant to CDK4/6 inhibitor plus aromatase inhibitor-based endocrine treatment and with homologous recombination deficiency, oncogenic driver activation and/or other molecular alterations associated with replication stress (RS) | |
| Phase 2Authorised | not given | Efficacy of Tuvusertib in Recurrent IDH mutant Astrocytoma with ATRX mutation, a phase II prospective trial. |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026